09969.HK
InnoCare Pharma Limited
HKSE · Healthcare · Biotechnology · CN
HKD 15.37
+4.06%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.8B | 2.3B | 1.0B | 738.5M | 625.4M |
| Cost of Revenue | 279.4M | 285.2M | 138.4M | 128.4M | 143.4M |
| Gross Profit | 2.5B | 2.0B | 871.0M | 610.1M | 482.0M |
| Operating Expenses | |||||
| R&D Expense | 954.0M | 849.2M | 814.0M | 751.2M | 639.1M |
| SG&A Expense | 784.0M | 759.5M | 310.6M | 252.1M | 489.6M |
| General & Admin Expense | 92.8M | 179.2M | 47.9M | 48.6M | 51.0M |
| Selling & Marketing Expense | 313.2M | 580.0M | 262.8M | 203.6M | 438.6M |
| Other Expenses | 23.4M | (37.0M) | 272.1M | 258.0M | 123.7M |
| Total Operating Expenses | 1.8B | 1.6B | 1.4B | 1.3B | 1.3B |
| Cost and Expenses | 2.0B | 1.9B | 1.5B | 1.4B | 1.4B |
| Operating Income (EBIT) | 713.3M | 440.6M | (525.8M) | (651.2M) | (770.4M) |
| Non-Operating | |||||
| Interest Income | 157.5M | 152.0M | 171.6M | 192.3M | 136.9M |
| Interest Expense | 56.0M | 53.6M | 33.8M | 35.0M | 17.0M |
| Net Interest Income | 101.4M | 98.3M | 137.8M | 157.3M | 119.9M |
| Other Non-Op Income/Expense | 212.3M | 198.2M | 73.2M | 6.9M | (123.3M) |
| Non-Operating Income (excl Interest) | 21.8M | — | (10.1M) | (42.0M) | 145.5M |
| EBT (Pre-Tax Income) | 921.3M | 638.8M | (452.6M) | (644.2M) | (893.7M) |
| Income Tax Expense | 13.9M | 11.3M | 263.0K | 1.4M | (22.1M) |
| Bottom Line | |||||
| Net Income | 907.3M | 625.8M | (440.6M) | (631.3M) | (886.6M) |
| Earnings from Cont. Ops | 907.4M | 627.5M | (452.9M) | (645.6M) | (893.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 907.3M | 625.8M | (440.6M) | (631.3M) | (886.6M) |
| Per Share | |||||
| Basic EPS | HK$0.52 | HK$0.36 | (HK$0.26) | (HK$0.37) | (HK$0.60) |
| Diluted EPS | HK$0.52 | HK$0.36 | (HK$0.26) | (HK$0.37) | (HK$0.60) |
| Revenue Per Share | HK$1.56 | HK$1.30 | HK$0.60 | HK$0.43 | HK$0.42 |
| Shares | |||||
| Basic Shares Outstanding | 1.8B | 1.8B | 1.7B | 1.7B | 1.5B |
| Diluted Shares Outstanding | 1.8B | 1.8B | 1.7B | 1.7B | 1.5B |
| Profitability Metrics | |||||
| EBITDA | 862.7M | 555.9M | (463.5M) | (516.6M) | (808.3M) |
| D&A | 107.4M | 115.3M | 58.0M | 92.6M | 68.4M |
| EBIT | 785.0M | 440.6M | (521.5M) | (609.2M) | (876.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026